Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University)

N/A

Report date: 2022/08/23 10:13:30

Base Information

Drug NameDual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University)
Drug Alias NameChimeric antigen receptor T-cells targeting CD19/CD22CD19-22.BB.z-CAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford UniversityOrca Biosystems Inc
China Registration ClassN/A

Develop Information

Active CompaniesStanford University
Inactive CompaniesN/A
Active IndicationsNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A